Latest News | Aug 19, 2023

The Week in Review in Prescription Drug Pricing

Special Edition! The Inflation Reduction Act turns 1! 🎂🎈

Welcome to the Week in Review.

This week marked the one year anniversary of the passage of the historic Inflation Reduction Act. The Biden administration and members of Congress eagerly spreadthe word about how the widely supported drug price law is providing relief to patientsin their states and the soon-to-be implemented provisions will continue to lower costs.
 
ICYMI, here’s a quick roundup of how we at P4AD celebrated and defended the drug price provisions in the Inflation Reduction Act on it’s one year anniversary: 

1.  Launch Of P4AD’s Bilingual Advocacy Hub

 2.  Amicus Brief, Rally, And Petition To Stop Medicare Negotiation Lawsuits

3. New Op-Ed Defending Medicare Negotiation

Have a great weekend! 

Patients Across The Country Are Feeling Relief From The Law’s Drug Price Reforms And Will Continue To Pay Lower Prices In Years To Come

WASHINGTON, D.C. — On the one year anniversary of the passage of the Inflation Reduction Act, Patients For Affordable Drugs Now (P4ADNow) marked the moment by launching a Spanish language version of its advocacy hub, es.medicarenegotiation.org. The site includes an explanation and timeline of the Inflation Reduction Act drug price reforms and tools for advocates to share their story and take action.

“Patients For Affordable Drugs Now is thrilled to celebrate the one year anniversary of the drug price provisions in the Inflation Reduction Act by launching our advocacy hub in Spanish,” said Merith Basey, executive director of Patients For Affordable Drugs Now. “Latinos, many of whom are Spanish speakers, are disproportionately impacted by high drug prices and as part of our commitment to lowering drug prices we want to ensure more patients across the country are not only made aware of these new provisions, but understand how they will be able to benefit from them now and in the future.” 

Patient advocates like Maria Sanchez of Atlanta, Georgia, are already feeling the impacts of the new law. Maria takes Toujeo insulin to manage her diabetes. Before the Inflation Reduction Act, a box of three pens was priced at $259.

“Now, Medicare Part D copays for insulin are capped at $35 for a month’s supply. This copay cap for insulin has saved me money that I can use to buy healthier food for my family, visit my grandchildren more often, or no longer skip out on my test strips,” Maria shared. “These savings will bring consistency to my payments, improve my quality of life, and allow me to purchase the drugs and health supplies I need.”

The groundbreaking drug price reforms in the Inflation Reduction Act, which passed August 16, 2022, included:

P4ADNow’s advocacy hub is available in Spanish here and in English here.

————————-

P4ADNow Celebra Un Año De Aniversario De La Ley De Reducción De La Inflación Con El Lanzamiento De Herramienta Digital En Español

Pacientes Alrededor Del País Se Sienten Aliviados Por Las Reformas De Los Precios De Los Medicamentos Y Continuarán Pagando Precios Más Bajos En Los Años Que Vienen

WASHINGTON, D.C. — En el primer aniversario de la aprobación de la Ley de Reducción de la Inflación, Patients For Affordable Drugs Now (P4ADNow), marcó el momento con el lanzamiento de una versión en español de su herramienta digital, Es.medicarenegotiation.org. El sitio incluye una explicación y un cronograma de las reformas en los precios de medicamentos de la Ley de Reducción de la Inflación y herramientas para que activistas compartan su historia y tomen acción. 

“Patients For Affordable Drugs Now se complace en celebrar el primer aniversario de las provisiones de los precios de medicamentos en la Ley de la Reducción de la Inflación al lanzar nuestro centro de defensa en español,” dijo Merith Basey, directora ejecutiva de Patients For Affordable Drugs Now. “Los Latinos, muchos de los cuales son hispanohablantes, son desproporcionadamente afectados por los precios altos de los medicamentos y como parte de nuestro compromiso de reducir los precios de los medicamentos, queremos asegurarnos de que más pacientes en todo el país no solo estén al tanto de estas nuevas provisiones, sino que comprendan cómo ellos podrán beneficiarse de ellos ahora y en el futuro”. 

Pacientes defensores como Maria Sanchez de Atlanta, Georgia, ya están sintiendo los impactos de la nueva ley. Maria toma la insulina Toujeo para controlar su diabetes. Antes de la Ley de la Reducción de la Inflación, una caja de tres injecciones tenía un precio de $259. 

“Ahora, los copagos de la Parte D de Medicare para la insulina tienen un tope de $35 por el suministro de un mes. Este tope de copago para la insulina me ahorrado dinero que puedo usar para comprar alimentos más saludables para mi familia, visitar a mis nietos con más frecuencia o dejar de faltar mis tiras reactivas”, compartió Maria. “Estos ahorros traerán consistencia a mis pagos, mejorarán mi calidad de vida, y me permitirán comprar los medicamentos y suministros de salud que necesito.”

Las reformas pioneras de los precios de medicamentos en la Ley de la Reducción de la Inflación, que se aprobó el 16 de Agosto, 2022, incluyeron: 

El herramienta digital de P4ADNow está disponible en español aqui y en inglés aqui

###

Welcome to the Week in Review.

1.  Report Update: Hiding In Plain Sight

 2.  Momentum For Drug Price Reforms In Senate

3.   The Inflation Reduction Act Brings On The Savings!

BONUS: In this edition of Big Pharma’s shady behavior: Drug companies shift profits overseas to low-tax jurisdictions in order to line their coffers with billions of dollars. People in the United States pay some of the highest drug prices in the world and receive “none of the benefits” from the U.S. pharmaceutical industry, reportedBusiness Insider.

Have a great weekend! 

Happy 58th Birthday, Medicare! Only 7 more years until you’re eligible for yourself 🥳

Welcome to the Week in Review.

1.  The Inflation Reduction Act: Building on Medicare’s Reach To Patients

 2.  Buildup To September’s Congressional Session

3.  Patent Abuse: “Profits At Any Price”

BONUS: P4AD submitted comments to the NIH ahead of its workshop Monday, calling on the agency to address the issue of fair pricing for all NIH and taxpayer-funded drugs and make the workshop patient-centered. Worth a read!

Have a great weekend! 

Congress may be in recess, but we’ll be busy writing letters to our Senators to pass bipartisan drug price reforms that boost competition and curb patent abuse!

Image

Welcome to the Week in Review.

1.  Senate Takes on PBM and Patent Reforms

 2.  Debunking Pharma Doublespeak

3.  The Inflation Reduction Act: More Savings For Patients

Have a great weekend!

Historic things happening this summer: BarbieNeopets relaunch, and Medicare releasing the names of 10 negotiated drugs. C’mon Barbie, time to check on your lower drug prices.  

Welcome to the Week in Review.

1.  Medicare Negotiation: Popular Provisions That Will Bring Relief 

 2.  Momentum Builds On PBM Reforms

3.  Continuing The Push For Competition

BONUS: It’s been almost a year since the Inflation Reduction Act passed and despite Big Pharma fear mongering, drug companies seem to be doing just fine! This week, Novartis announced a $15 billion share buyback and J&J published its quarterly earnings, which increased 6.3% for a total of $25.5 billion in sales. What was that about not enough money for R&D? 👀

Have a great weekend!

Special Edition! All About The:

Welcome to the Week in Review.

ICYMI, Senate Majority Leader Schumer sent a Dear Colleague letter indicating his intention to advance bipartisan bills to lower drug costs during the July work period. Then on Thursday, we launched the Push For Competition To Lower Drug Prices,” calling on the Senate to immediately pass bipartisan drug price competition reforms. Here’s a recap:

BONUS: Speaking of Big Pharma patent abuse, did you see that John Green called out Johnson & Johnson for seeking secondary patents on tuberculosis drug bedaquiline to maintain its monopoly on the drug? This shady move denies millions of people access to the drug. Worth a watch (plus follow the conversation on #patientsoverpatents, which has been trending on Twitter)!

Have a great weekend! 

Senators, Patients, AARP, P4ADNow, and SPACEs in Action Launch Push At Press Conference 

WASHINGTON, D.C. — Senator Klobuchar, patients, AARP, Patients For Affordable Drugs Now (P4ADNow), and SPACEs in Action launched the “Push For Competition To Lower Drug Prices” with a press conference on Capitol Hill today. To kick off the push, 35 organizations representing patients, consumers, seniors, churches, students, unions and disease advocacy groups sent a letter to the Senate calling for immediate passage of bipartisan bills that crack down on the drug industry’s anti-competitive practices and close regulatory loopholes to promote generic and biosimilar competition to lower drug prices for patients. 

“Right now, drug companies abuse our system through anti-competitive practices that extend monopolies beyond the time intended under law, leaving patients in this country paying more than three times what other wealthy nations pay for the exact same brand name drugs,” said David Mitchell, a patient with incurable blood cancer whose drugs carry a list price of more than $900,000 per year and founder of Patients For Affordable Drugs Now. “The Senate has the chance to pass a package of bipartisan bills that will reform and improve our patent and regulatory systems to encourage earlier market entry of more affordable generics and biosimilars. These are common sense, bipartisan solutions that will deliver real relief to patients through lower drug prices. We urge the Senate to act now.”

As part of the kickoff, today P4ADNow also launched new digital ads and an advocacy hub for people to urge their Senators to pass a package that includes bipartisan bills that promote generic and biosimilar competition to lower drug prices. 

This press conference took place following Majority Leader Schumer’s Dear Colleague letter indicating his intention to advance bipartisan bills to lower drug costs during the July work period. The package includes reforms voted out of the Senate HELPJudiciary, and Commerce Committees on a strong bipartisan basis earlier this year.

The following are quotes from the speakers at today’s press conference: 

“Sky-high prices have kept prescription medications out of reach for far too many Americans. By passing legislation to address the anti-competitive tactics that big pharma uses to keep drug prices high, we will enable more competition and innovation in the pharmaceutical market and lower costs for patients,” said Senator Klobuchar. “I’ll keep working to ensure all Americans can get the life-saving medications they need at prices they can afford.” 

“Americans can’t afford to pay more than 3 times what people in other countries pay for the same medicine,” said Nancy LeaMond, AARP Executive Vice President and Chief Advocacy and Engagement Officer. “Generic drugs have proven to be one of the safest and most effective ways to ensure that millions of older Americans can afford the prescription drugs they need. Now is the time for Congress to increase competition and help lower drug prices.” 

“Lowering drug prices will increase the quality of life for many people like me across this country. We are urgently calling on the Senate to immediately advance and pass the bipartisan bills to lower drug prices.” – Arthur Blair, Board Member, SPACES in Action

“Big Pharma is abusing the system and taking advantage of patients by preventing competition for life-saving drugs to protect its bottom line – people like me have no choice but to pay whatever price the companies set…It’s time to put patients’ lives ahead of drug industry profits.” – Jacqueline Garibay, 22-year-old ankylosing spondylitis patient from Austin, TX 

A recording of the event can be viewed here, and photos are available upon request.

###